NCT06933693 Mixed Vs Blocked Search: Four Unique Tasks
| NCT ID | NCT06933693 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Brigham and Women's Hospital |
| Condition | Vision |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2029-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-06-01 with a primary completion date of 2029-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal is to look for qualitative differences in visual search behavior when one search is performed many times in a row compared to when multiple search tasks are intermixed. Four search tasks are tested. In the Mixed condition, the four tasks are randomly changed from trial to trial. In the Blocked condition, each task is run as a block of 100 trials.
Eligibility Criteria
Inclusion Criteria: * Pass Ishihara color vision test Exclusion Criteria: * vision less than 20/25 with correction * history of neuromuscular or visual disorders
Contact & Investigator
Jeremy M Wolfe, PhD
PRINCIPAL INVESTIGATOR
Brigham and Women's Hospital
Frequently Asked Questions
Who can join the NCT06933693 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Vision. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06933693 currently recruiting?
Yes, NCT06933693 is actively recruiting participants. Contact the research team at jwolfe@bwh.harvard.edu for enrollment information.
Where is the NCT06933693 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06933693 clinical trial?
NCT06933693 is sponsored by Brigham and Women's Hospital. The principal investigator is Jeremy M Wolfe, PhD at Brigham and Women's Hospital. The trial plans to enroll 40 participants.